NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has entered into a research collaboration with Ameritox to evaluate the use of Agilent's RapidFire platform in medication monitoring.
The RapidFire system is a high-throughput mass spectrometry platform that was developed for drug screening by Biocius, a spinout of BioTrove that Agilent acquired two years ago. The RapidFire 360 system was launched in May 2010 for the high-throughput screening of in vitro ADME assays.
Agilent said that the collaboration with Ameritox is one of the first for use of the RapidFire system in the field of medication monitoring. Can Ozbal, director of Agilent's RapidFire business, said that Ameritox is using the system to streamline analysis of small panels of exogenous compounds compared to traditional methods of analysis.
Ameritox is a Baltimore-based provider of pain management services, including lab testing.
Terms of the alliance were not disclosed.